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Neurological diseases have placed heavy social and ﬁnancial burdens onmodern society. As
the life expectancy of humans is extended, neurological diseases, such as Parkinson’s dis-
ease, have become increasingly common among senior populations. Although the enigmas
of Parkinson’s diseases await resolution, more vivid pictures on the cause, progression, and
control of the illness are emerging after years of research. On the molecular level, GTPases
are implicated in the etiology of Parkinson’s disease and are rational pharmaceutical targets
for their control. However, targeting individual GTPases, which belong to a superfamily
of proteins containing multiple members with a conserved guanine nucleotide binding
domain, has proven to be challenging. In contrast, pharmaceutical pursuit of inhibition of
kinases, which constitute another superfamily of proteins with more than 500 members,
has been fairly successful. We reviewed the breakthroughs in the history of kinase drug
discovery to provide guidance for the GTPase ﬁeld.We summarize recent progressmade in
the regulation of GTPase activity.We also present an efﬁcient and cost effective approach
to drug screening, which uses multiplex ﬂow cytometry and mixture-based positional
scanning libraries. These methods allow simultaneous measurements of both the activity
and the selectivity of the screened library. Several GTPase activator clusters were identiﬁed
which showed selectivity against different GTPase subfamilies.While the clusters need to
be further deconvoluted to identify individual active compounds, the method described
here and the structure information gathered create a foundation for further developments
to build upon.
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INTRODUCTION
Parkinson’s disease is a degenerative disorder occurring in the
central nervous system (Shulman et al., 2011). Early symptoms
are mostly movement related which include shaking, rigidity and
slowness. As the disease progresses, thinking and behavior prob-
lems may arise with dementia common at the advanced stage.
Diagnosis is usually based on symptoms, andneuroimaging is used
for conﬁrmation (Jankovic, 2008). Parkinson’s disease is associated
with loss of neurons in the substantia nigra of the midbrain and
accumulation of Lewy bodies, which are aggregates of the protein
α-synuclein, in the remaining neurons that generate insufﬁcient
dopamine. Parkinson’s disease affects 1% of the population above
age 60 and 4% of the population over 80 (de Lau and Breteler,
2006). The disease has put a huge ﬁnancial burden on society
costing around 23 billion dollars in the US each year (Findley,
2007). Epidemiological studies have linked exposure to pesticides
as a provocative environmental factor (Freire and Koifman, 2012).
However, the detailed cause and mechanism of the disease are still
ill-deﬁned. With the accumulated genetic information available,
familial causes of the disease have emerged although representing
a lesser percentage (Davie, 2008).
While exploring the origins of the Parkinson’s disease, pro-
teins from various families with different functions have been
suggested to contribute to its occurrence at the molecular level.
One of them is the GTPase family. Multiple GTPases have
been identiﬁed through genetic studies to be causal factors.
GTPases are guanine nucleotide binding proteins which switch
between GTP and GDP binding states. These proteins play
important roles in various cellular processes, such as division,
signal transduction, protein synthesis, and vesicle transport.
Based on their functions, GTPases are grouped as small Ras
superfamily GTPases, large GTPases, heterotrimeric G pro-
teins, and translation factor family GTPases. In spite of size
differences, these proteins have a conserved and globular gua-
nine nucleotide binding domain which constitutes α-helixes,
β-sheets, and switch I and II regions (Figure 1). GTPases can
intrinsically hydrolyze GTP to GDP. However, the conversion
between GTP and GDP is most often regulated by guanine
nucleotide exchange factors (GEFs) which facilitate GDP dis-
sociation and GTP binding, and GTPase activating proteins
(GAPs) which increase the hydrolytic activity of GTPases and
convert GTPases to the GDP bound state. For large GTPases,
the hydrolysis of GTP powers organelle reorganization, while
for small GTPases, the hydrolysis inactivates the proteins since
the GDP binding conformation cannot interact with downstream
effectors.
Frontiers in Molecular Neuroscience www.frontiersin.org June 2014 | Volume 7 | Article 52 | 1
Hong and Sklar Targeting GTPases in Parkinson’s disease
FIGURE 1 | GTPase domain core structure. (A) Human Ras small GTPase
with GTP bound. Six stranded β-sheets are surrounded by ﬁve α-helices
(PDB: 121p). (B) Dictyostelium dynamin large GTPase with GDP bound.
Eight stranded β-sheets are surrounded by nine α-helices (PDB: 1jwy).
Helices are shown in red, β-sheets in blue, switch region in white, and the
guanine nucleotide in yellow. Though the nucleotide identities are different
for the two structures, the compact and globular arrangement is
conserved. BothTiff ﬁles were taken from www.endocytosis.org/
Dynamin/GTPbinding-motifs.htm. (C) Overlaid structures of three inhibitors
with GDP bound K-Ras G12C. These allosteric inhibitors bind to switch-II
region and induce an inactive GDP binding conformation (Ostrem et al.,
2013).
In this review, we discuss the association of GTPases with
Parkinson’s disease and the potential for them to be the phar-
maceutical targets. To shed light on GTPase drug discovery in
more general terms, the milestones in the productive kinase ﬁeld
are summarized. We also describe recent progress in the search
for GTPase activity regulators, including a pilot combinatorial
library approach against multiple small GTPases that have been
implicated in Parkinson’s disease and other disorders.
PHYSIOLOGICAL PROCESSES ASSOCIATED WITH
PARKINSON’S DISEASE AND GTPASE INVOLVEMENT
Years of study have yielded some clues to the etiology of Parkin-
son’s disease. Several physiological processes are speculated to
be linked to the cause and progression of the disease at the
cellular level. These include organelle homeostasis and traf-
ﬁc, mitochondria ﬁssion and fusion, axon growth, neuron
cell morphogenesis and survival, oxidative damage repair, and
etc. GTPases, including large motor GTPases and small Ras
superfamily GTPases, have been found to be involved in these
processes. The important roles that they play are described
(Figure 2).
GOLGI AND α-SYNUCLEIN AGGREGATE CLEARANCE
Genetic linkage studies have linked gene PTEN induced puta-
tive kinase 1 (PINK1) and PARK2 to Parkinson’s disease (Wang
et al., 2011) while both the genetic linkage studies (Paisan-Ruiz
et al., 2006) and genome wide association studies (GWAS; Simon-
Sanchez et al., 2009) have identiﬁed leucine-rich repeat kinase 2
(LRRK2) to be genetically linked and associated with the disease.
Among them, LRRK2 encodes a large multi-domain protein con-
taining a Ras-of-complex (ROC) GTPase domain, a C-terminal
of Roc (COR) domain and a serine/threonine kinase domain.
The COR domain connects the GTPase and the kinase domain
(Tsika and Moore, 2013). It has been suggested that the kinase
and GTPase activity mutually affect each other, so that the GTP or
GDP binding capacity of ROC induces kinase activation (Tay-
mans et al., 2011) and the activated kinase phosphorylates the
GTPase domain which alters conformation to further promote
kinase activity (Gloeckner et al., 2010). Nonetheless, the detailed
mechanism is still unresolved (Taymans, 2012). The most com-
mon mutation of LRRK2 found in Parkinson’s disease is G2019S
in the kinase domain (Tsika and Moore, 2013). This mutation
increases kinase activity. Another common mutation is R1441C
which is in the GTPase domain (Tsika and Moore, 2013). There
have been conﬂicting results regarding the effects of the R1441C
mutation on GTP binding. However, it has been consistently
demonstrated that GTPase hydrolysis activity was reduced with
the mutation (Lewis et al., 2007; Daniels et al., 2011). Parkin-
son’s disease with mutations in the GTPase domain shows pure
nigral neuron degeneration without severe Lewy body formation.
Though most LRRK2 studies have been directed to control the
kinase activity, it has been found that long term inhibition of LRRK
kinase activity through genetic knockout has unwanted side effects
including susceptibility to inﬂammatory bowel syndrome and kid-
ney dysfunction (Herzig et al., 2011; Liu et al., 2011; Baptista et al.,
2013). Considering the mutual regulation between the kinase and
the GTPase domain, an alternative solution is to control the activ-
ity of the GTPase domain.We anticipate attempts to decrease GTP
binding throughminimizing the interactions between the GTPase
domain and its GEFs, or efforts to increase the GTPase hydrolysis
activity through controlling its GAPs could be explored (Anand
and Braithwaite, 2009; Gandhi et al., 2009; Cookson, 2010; Tsika
and Moore, 2013).
As for themechanism of LRRK2 involvement in the pathogene-
sis of Parkinson’s disease, studies have shown that LRRK2 regulates
the degradation of defective Golgi, an organelle that contributes
to synaptic vesicle formation (Beilina et al., 2014). Mutations in
LRRK2 therefore lead to errors in vesicular endocytosis and recy-
cling. By screening against protein interaction arrays, LRRK2 was
found to complex with several proteins (Beilina et al., 2014). The
complex is important for the clearance of Golgi-derived vesicles
through the autophagy-lysosome system. Both Golgi clearance
and autophagy have been implicated in neuron loss in Parkinson’s
disease (Fujita et al., 2006). Each protein of the complex, which is
likely formed using LRRK2 as a scaffold, contributes to the Golgi
clearance function. One of them, the GTPase Rab7L1 (MacLeod
et al., 2013; Beilina et al., 2014), is a cytosolic GTPase belonging to
the Rab family of GTPases. ThisGTPase has been shown to localize
at the Golgi and regulate the vesicular sorting (MacLeod et al.,
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FIGURE 2 | Physiological processes related to the Parkinson’s
disease and the GTPases and the effectors involved. GTPases
LRRK2, Rab7L1, Rab5, and GTPase effector ArfGAP1 regulate Golgi
and α-synuclein aggregate clearance; large GTPases MFN1, MFN2,
OPA1, and DRP1 regulate mitochondria ﬁssion and fusion; MIRO and
Rheb have a role in organelle transport and axon maintenance;
GTPase Rho, Rac1, and kinase effector ROCK are involved in oxidative
stress management and neuroinﬂammation; Rho, Rit, and Rin are
involved in neuronal differentiation and survival. LRRK2, leucine-rich
repeat kinase 2; ArfGAP1, ADP-ribosylation factor GTPase-activating
protein 1; MFN1 and MFN2, mitofusin-1 and mitofusin-2; OPA1, optic
atrophy 1; DRP1, dynamin-related protein 1; MIRO, mitochondrial
Rho-GTPase; Rheb, Ras homolog enriched in brain; ROCK,
Rho-associated protein kinase.
2013). Constitutively active Rab7L1 effectively suppressed neurite
shortening induced by LRRK2mutations. Moreover, genetic stud-
ies showed that alterations at the Rab7L1 gene promoter are likely
to enhance the expression of the gene locus and are associated with
reduced Parkinson’s disease risk (Gan-Or et al., 2012).
In another study, LRRK2 was also found to interact with
GTPase Rab5b at the endosome in neurons which has estab-
lished roles in regulating endocytosis (Shin et al., 2008). Moreover,
LRRK2 interacts and phosphorylates aGAP,ADP-ribosylation fac-
tor GTPase-activating protein 1 (ArfGAP1). Silencing ArfGAP1
expression was shown to protect against mutant LRRK2 induced
neurite shortening, suggesting that ArfGAP1 might also be a
potential target in the Parkinson’s disease (Stafa et al., 2012; Xiong
et al., 2012).
Maintaining normal homeostasis is important for cell health.
Not only defective organelles but also protein aggregates need
to be removed over time. Aggregates of the α-synuclein pro-
tein can form Lewy bodies that are commonly found in neurons
with Parkinson’s disease. Biochemical studies have demonstrated
that α-synuclein and Rab3a form a complex at the presynap-
tic membrane (Chen et al., 2013). Rab3a mutants with deﬁcient
GTPase activity blocked α-synuclein dissociation from the mem-
brane. Although it is still controversial whether the sequestra-
tion of α-synuclein contributes directly to Parkinson’s disease
or is associated with the disease phenotype, there appears to
be a link between the intracellular level of α-synuclein and
Rab3a.
Moreover, age-dependent α-synuclein accumulation could
interfere with how cells cope with stress by blocking protein
interactions that regulate GTPase activities. α-Synuclein in Lewy
bodies was phosphorylated at Ser129 by Polo-like kinase (Plk2)
both in vitro and in vivo (Wang et al., 2012a). Plk2 also interacts
with and phosphorylates the GEF and/or GAPs of small GTPase
Rho1. By activating downstream protein kinase C, Rho1 is an
import signaling node in the mitogen-activated protein kinase
(MAPK) cascade response to cell stress. When the concentration
of α-synuclein is high, α-synuclein occupies Plk2 and inhibits the
interaction between Plk2 andRho1GEFs and/GAPs. Therefore the
intracellularGTP-boundand activeRho1decreases to a level insuf-
ﬁcient to respond to cell stress. Accumulation of such cell defects
eventually lead to cell death and neuron loss is characteristic of
Parkinson’s disease.
Therefore, both the cause and the consequence of α-synuclein
aggregation have GTPase involvement. It is possible that by regu-
lating GTPase activity, the formation of the α-synuclein aggregate
could be reduced and its effect minimized.
MITOCHONDRIA FISSION AND FUSION
Mitochondria are crucial for cell energy production and oxida-
tion control. It has been recognized that the organelle undergoes
dynamic ﬁssion and fusion changes. In neurons, mitochondrial
ﬁssion can provide energy at sites of demand, while mitochon-
dria fusion can regenerate mitochondrial DNA and protein after
neurotoxic insult. Mounting evidence shows that dysregulated
mitochondria ﬁssion and fusion contributes to Parkinson’s disease
(Knott et al., 2008).
The dynamic ﬁssion and fusion of mitochondria is regulated
by a group of large GTPases. The initial studies conducted in
yeast have provided insight into mammalian cells (Knott et al.,
2008). Mitofusin-1 and mitofusin-2 (MFN1 and MFN2) are large
mammalian GTPases localized at the outer membrane of the
mitochondria and direct the organelle fusion by interacting with
anotherGTPasemitochondrial Rho-GTPase (MIRO). The amino-
terminus of MFN1 and MFN2 contains the conserved GTPase
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domain while the carboxy-terminus contains a coiled-coil struc-
ture. Mutations in the GTPase domain of their yeast orthologs
inhibit mitochondrial fusion. Also in yeast, the inner mitochon-
drial membrane fusion is regulated by the large GTPase Mgm1,
likely through trans interactions between the GTPase domain and
the GTPase effector domain (GED). The mammalian ortholog
OPA1 may play a similar role. As for the ﬁssion of the mitochon-
dria, large GTPase dynamin-related protein 1 (DRP1) is likely
involved. Inferred from studies on the yeast ortholog dynamin
1 (Dnm1), DRP1 can form oligomers at the ﬁssion site while
hydrolysis of GTP induces DRP1 to assume a conformation that
helps enhances ﬁssion. Both Dnm1 and DRP1 have three con-
served domains including an N-terminal GTPase, a central helical
domain and a GED domain. A direct interaction between LRRK2
and DRP1 has also been demonstrated. Parkinson’s disease related
mutations in the GTPase domain of LRRK2 enhanced the inter-
action and was shown to increase mitochondria fragmentation
(Wang et al., 2012c). It has also been shown that inhibition of the
large GTPase DRP1 protected neuron death both in vitro and
in vivo (Grohm et al., 2012; Qi et al., 2013).
ORGANELLE TRANSPORT ALONG AXONS AND AXON MAINTENANCE
Intracellular transport of organelles such as Golgi and mitochon-
dria is important for maintaining healthy neurons by providing
necessary substances and energy at remote synapses as well as
clearing unwanted waste (Sheng and Cai, 2012; Millecamps and
Julien, 2013). Errors inmitochondriamovement have been associ-
ated with Parkinson’s disease (Liu et al., 2012). The characteristic
α-synuclein aggregation of Parkinson’s disease was shown to
impede the movement of organelles along the axons by directly
interacting with axon motor proteins. The stalling of vesicles
triggered a cascade of signals that lead to neuron death (Li
et al., 2004). Several GTPases have been linked to the regulation
of organelle transport. Besides its role in mitochondria fusion,
GTPase MIRO and its adaptor proteins have also been shown
to control the movement of the mitochondria (Fransson et al.,
2003; Frederick et al., 2004). The GTPase anchors kinesin to
the mitochondria surface to facilitate its trafﬁc along the axons.
The small GTPase Rab7 has also been shown to control endoso-
mal and lysosomal retrograde transport (Millecamps and Julien,
2013).
Moreover, two genes, PINK1 and PARK2, found to link to
Parkinson’s disease from genetic linkage studies encode protein
PINK1 and Parkin. Mutations of the two proteins are often
found in early onset familial forms of the Parkinson’s disease
(Wang et al., 2011, 2012b). PINK1 is a serine/threonine kinase
while Parkin is an E3 ubiquitin ligase. The two proteins have
been shown to cooperatively promote the ubiquitination and
degradation of MIRO at the mitochondria outer membrane
(Liu et al., 2012). The fusion and transport of mitochondria
need to be checked since defective mitochondria might help to
spread protein aggregates and be neurotoxic. PINK1 and Parkin
therefore serve as mitochondria quality control checkpoints.
Mutations in PINK1 and Parkin can cause aberrant mitochon-
drial homeostasis allowing the dysfunctional mitochondria to
evade being engulfed by mitophagy and survive to be neurotoxic
(Liu et al., 2012).
In Parkinson’s disease, it is suspected that the axon of the
dopamine producing neuron plays a more important role than
the cell body at the beginning stage, and it is the loss of the
axon, rather than the cell body, that determines disease progres-
sion (Luo, 2000). Themammalian target of rapamycin (mTor) is a
mediator of PI3K/Akt signaling. The PI3K-Akt-mTor pathway has
been shown to participate in the neuron axon growth and main-
tenance by controlling axon number, branching, and growth cone
dynamics (Kim et al., 2012). The GTPase Ras homolog enriched
in brain (Rheb) is an upstream regulator which can activate mTor.
By applying adeno-associated virus vector transduction, it was
shown that the constitutively active GTPase Rheb could protect
neurons in both normal adult mice and mice treated with neuro-
toxin through inducing axon sprouting and regrowth (Luo, 2000;
Kim et al., 2012).
OXIDATIVE STRESS AND NEUROINFLAMMATION
It has been shown that oxidative stress and neuroinﬂammation
play a role in the pathogenesis and progression of Parkinson’s
disease (Hirsch et al., 2012). Although the downstream signaling
has not yet been elucidated, the Rho GTPase has been shown to
upregulate themolecules that enhance inﬂammation andoxidative
stress. When dopaminergic cells were treated with neurotoxins,
Rho and Rho-associated protein kinase (ROCK) were activated,
either directly or indirectly via the NADPH oxidase, and caused
cell death. A ROCK inhibitor has been shown to alleviate the
neurotoxin effect (Villar-Cheda et al., 2012). However, the effects
of Rho GTPase might be multifaceted. In another study, Rho and
ROCK were activated by a merlin-iso2-dependent complex and
induced neuroﬁlament heavy chain phosphorylation (Whitehead
et al., 2009; Schulz et al., 2013). Down regulation of merlin-iso2 in
an animal model caused symptoms of neurological disorder.
Reactive oxygen species (ROS) produced during neurotoxic
stress could cause oxidative DNA damage and dopaminergic neu-
ronal degeneration. NADPH oxidase 1 (Nox1) and small GTPase
Rac1, an important regulator in the Nox1 system, were found
to accumulate in the dopaminergic neurons of patients with the
Parkinson’s disease (Choi et al., 2012). Moreover, in both cellular
and animal models, the expression levels of both proteins were
increased by neurotoxin treatment accompanied by the accumu-
lation of damaged DNAs. Pharmaceutical or genetic intervention
toward Nox1 or Rac1 attenuated the neurodegeneration.
NEURONAL DIFFERENTIATION AND SURVIVAL
Rit and Rin are members of a novel branch of Ras superfam-
ily GTPases and have been implicated in Parkinson’s disease by
GWAS (Latourelle et al., 2012; Pankratz et al., 2012). Rit and
Rin are involved in multiple cell survival signaling pathways
including ERK/MAPK and p38/MAPK. Cell culture studies have
suggested that Rit regulates neuron morphogenesis through the
MEK/ERK pathway, and dendritic remodeling possibly through
the p38/MAPK pathway. Rit knockout ﬂies showed reduced resis-
tance toward neurotoxic insults. Moreover, as regulators of the
cell actin cytoskeleton, the Rho GTPases have also been shown
to play important roles in neuronal morphogenesis. Mutations in
the signaling pathway of Rho GTPases have been associated with
neurological disorders (Luo, 2000).
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SUMMARY FOR PHARMACEUTICAL POTENTIAL
As has been discussed, multiple GTPases regulate various
physiological processes and their misbehavior has been associated
with the commencement and phenotype of Parkinson’s disease.
These GTPases belong to either large motor GTPases, which con-
tain GED and other domains besides the guanine nucleotide
binding domain, or small Ras superfamily GTPases, which typ-
ically have the small or globular guanine nucleotide binding
domain. Adirect link of someof theGTPases toParkinson’s disease
has been explored by genetically controlling their expression at
either the transcriptional or translational level. Aftermany studies,
the pathogenesis of the Parkinson’s disease is still poorly deﬁned
and the available treatments only slow down disease progression
at best. Additional therapies are obviously needed. Considering
the implications of the GTPases in the disease, these proteins
are legitimate molecular targets. In addition, small molecule
drugs have the potential advantage of ease of use and simplic-
ity of pharmacokinetics. Therefore, searching for small molecule
GTPases activity modulators is a reasonable approach. However,
the hunt has appeared quite challenging, especially in comparison
to kinases, another superfamily of proteins, members of which
have also been implicated in many human diseases. As a whole,
kinase drug discovery has been fairly productive. We summarize
here themilestones in that process in an effort to provide guidance
for the quest in the GTPase ﬁeld.
KINASE DRUG DISCOVERY RETROSPECTIVE
Kinases are superfamily proteins that catalyze the phosphorylation
of substrates and are important for cell signal transduction, pro-
liferation, differentiation, cell cycle, growth, and survival. With
more than 500 kinases encoded in the human genome, liter-
ally every signal transduction circuit has to involve at least one
phosphotransfer step (Zhang et al., 2009). A number of diseases
including cancer, inﬂammation, and neurological disorders are
caused by the misﬁring of kinases. Kinases therefore have been
drug targets with a long history. The kinases can be grouped
into several subclasses (Noble et al., 2004): tyrosine kinases, serine
threonine kinases, phosphatidylinositol 3′-kinases (PI3K), and cell
cycle regulation kinases. Most success has been achievedwith tyro-
sine kinases which can be further divided into receptor tyrosine
kinases and non-receptor tyrosine kinases. Although catalysis by
the different groups of kinases can be differentially regulated, the
catalytic domains are well conserved in sequence and structure.
The amino and carboxy termini form two separate lobe struc-
tures while the Mg-ATP complex sits in a deep cleft created by the
bilobe.
It is often the case that activating mutations and overexpres-
sion of kinases lead to uncontrolled proliferation. Therefore kinase
inhibitors are more commonly pursued than activators. Typically,
kinase inhibitors are divided into several groups (Zhang et al.,
2009): type I inhibitors bind to the ATP binding site and are com-
petitive toward ATP; type II inhibitors bind both ATP binding site
and a hydrophobic site created by the activation loop, usually in
a DFG (a motif in the activation loop) out conformation; type
III inhibitors bind to allosteric sites close to the ATP binding site;
type IV inhibitors covalently and irreversibly bind to the active site
cysteine residue of kinases.
From initial natural products that were found to have kinase
inhibition activity to the designed US Food and Drug Admin-
istration (FDA)-approved drugs, the history of kinase inhibitor
development represents a productive example for pharmaceutical
intervention.
Staurosporinewas originally isolated from the bacterium Strep-
tomyces staurosporeus in 1977 and found to have antifungal and
apoptosis-inducing activity (Omura et al., 1977). Earlier stud-
ies showed that staurosporine inhibited protein kinase C and
bound to the ATP binding site in a competitive mode (Okazaki
et al., 1988). Staurosporine is thus a prototypical type I inhibitor.
However, additional studies found that staurosporine was not
selective and inhibitedmultiple kinases (Ruegg andBurgess,1989).
This promiscuity precluded the compound from getting into
clinical trials. Nonetheless, the elucidated structure of kinase
CDK2 with staurosporine bound has contributed to the under-
standing of the interactions between the amino acids at the
ATP binding site and a competitive inhibitor. Fragments of the
staurosporine scaffold also helped to construct new compound
libraries. Midostaurin, a derivative of staurosporine, has been
studied for treatment of acute myeloid leukemia (Fischer et al.,
2010).
The ﬁrst FDA-approved and the most successful kinase
inhibitor to date is imatinib. The break point cluster–Abelson
tyrosine kinase (BCR–ABL) oncogene is formed in patients with
chronic myeloid leukemia and acute lymphoblastic leukemia by
fusing the BCR gene on chromosome 22 and the ABL tyrosine
kinase on chromosome 9. A compound was initially discovered
by screening chemical libraries to inhibit the overactive BCR–
ABL kinase (Druker et al., 1996). The lead was later modiﬁed to
enhance its binding afﬁnity and given the name imatinib which
receive FDA approval in 2001 (Druker et al., 2001). Imatinib was
also found to inhibit both wild type c-KIT and mutant c-KIT that
is often found in gastrointestinal stromal tumor (GIST) and was
approved to treat the disease (Blay, 2011). The crystal structure
showed that imatinib-bound BCR–ABL assumes a DFG-out inac-
tive conformation and therefore represents the ﬁrst generation
type II inhibitor.
GNF2 is an allosteric type III kinase inhibitor targeting the
BCL–ABL oncogene (Adrian et al., 2006). The compound did not
inhibit the full length or catalytic domain of c-ABL in biochemical
assays, butwas as potent as imatinib in cellular proliferation assays.
The crystal structure and molecule modeling showed that GNF2
bound to the myristate binding site of BCL–ABL. Therefore the
compound inhibits the oncogene through a non-ATP competitive
mechanism.
HKI-272 is a covalent inhibitor against epidermal growth factor
receptor kinase (EGFR) which is a biomarker for many diseases
including breast cancer, lung cancer, andbrain tumor glioblastoma
multiforme (Rabindran et al., 2004; Minami et al., 2007). HKI-
272 reacts with a nucleophilic cysteine residue in EGFR through
a Michael addition reaction and inhibits the autophosphorylation
as well as the activation of the receptor kinase.
The above compounds represent milestones in the produc-
tive area of kinase drug discovery. By early 2009, eleven kinase
inhibitors had received FDA approval for cancer treatment, and
tests for treating illness other than the approved indications were
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ongoing in late clinical trials. At the same time, ∼30 kinase tar-
gets were developed to be ready for Phase I clinical trials (Janne
et al., 2009; Zhang et al., 2009). The success in kinase drug discov-
ery undeniably surpasses what has been achieved when targeting
other superfamily proteins including histone acetyltransferases
andGTPases. In retrospect, the early discovery of kinase inhibitors
had serendipitous elements such as ﬁnding staurosporine. As
high throughput screening became available, the discovery process
entered a productive phase. A number of type I ATP-competitive
kinase inhibitors were identiﬁed. Lead compound optimization
resulted in drugs in clinical trials, some of which were eventually
approved. However, after the peak period, the movement slowed
down due to the exhaustion of the available ATP-binding scaf-
folds. Also, the drugs obtained often lost their effectiveness due
to drug resistance. Therefore, novel methods to inhibit kinases
were explored. First, inhibitors with different mechanisms other
than the competitive inhibition were pursued. These included
type II inhibitors which could lock the kinase in an inactive con-
formation, type III allosteric inhibitors, and type IV covalently
bound irreversible inhibitors. Drug selectivity is a common issue
when the target is a member of a large superfamily of proteins.
Type II and type III inhibitors are likely to have an improved
selectivity proﬁle since the binding site is not the conserved ATP
binding site. As for the type IV inhibitors, although the potency
has been increased, the toxicity issue still provides reservations
for drug developers. Moreover, as more crystal structures of
kinases with inhibitors bound are resolved, kinase drug discov-
ery has increasingly relied on structure-based rational design. This
includes lead optimizationwhich improves upon the existing com-
pound, structure-based design which generates novel compounds
based on the knowledge obtained from the available structures,
and fragment-based design where discrete fragments that bind to
different parts of a target are combined to generate a new com-
pound intended tohave improvedpotency and selectivity. Notably,
compound libraries generated by combinatorial chemical synthe-
sis have facilitated the discovery of new kinase inhibitors where
the library members can be individual compounds or compound
mixtures (Liu and Gray, 2006).
STATUS OF GTPASE DRUG DISCOVERY AND PERSPECTIVES
Like kinases, GTPases are not only implicated in neurologi-
cal disorders, they have also been associated with various other
human diseases including cancer and inﬂammation (Luo, 2000;
Shaw and Cantley, 2006; Tybulewicz and Henderson, 2009).
Therefore, GTPases as drug targets have been studied for sev-
eral decades. Initial studies discovered GTPase regulators that
obstructed GTPase membrane localization and subsequent acti-
vation through essentially inhibiting the lipid transferases that
prenylate or geranylate the GTPases. However, the unselective
inhibition of the lipid transferases caused severe toxicity (Kon-
stantinopoulos et al., 2007). Compared with the success achieved
in the ﬁeld of kinase drug discovery, there have not yet been
drugs directly targeting GTPases proceeding into late clinical tri-
als. The scenario is likely caused by several factors. First, the
GTP binding domain of GTPases is relatively small and assumes
a smooth and globular structure (Milburn et al., 1990; Niemann
et al., 2001; Golen, 2010). This makes it difﬁcult to ﬁnd a drug
binding pocket. Second, the binding afﬁnity of the guanine
nucleotide toward the GTPases is high making other molecules
difﬁcult to compete against (John et al., 1990; Bourne et al., 1991).
Third, there have been multiple established biochemical and cel-
lular assay methods, and animal models for kinase inhibitor
discovery and characterization. However, these have been rela-
tively sparse for GTPases (Milligan, 2003; Labrecque et al., 2009).
Moreover, testing GTPase activity in vitro normally requires high
nanomolar to low micromolar enzymes, while kinase biochem-
ical assays usually only need low nanomolar enzymes due to
their high enzymatic activity (Taymans, 2012). Fourth, the activ-
ity of the GTPases is regulated by separate proteins like GEF
and GAPs, instead of other domains in the same protein as
in the case of kinases (Vigil et al., 2010). Finally, in compar-
ison to kinases whose functions are mainly involved in signal
transduction, GTPases appear to play more diverse roles in cell
physiology ranging from cytoskeletal changes to protein trans-
lation. Therefore, toxicity from unwanted side effects can be
severe (de Boer et al., 2007). Also, while overactive kinases may
be problematic, both overactive and deﬁcient GTPases have been
implicated in human diseases (Sahai and Marshall, 2002). There-
fore, both GTPase inhibitors and activators should be considered
for different circumstances. The differences in the drug discov-
ery process targeting kinases and GTPases are summarized in
Table 1.
Nonetheless, powered by accumulating structural knowledge
and the lessons learned from kinase drug discovery,much progress
Table 1 | Comparison of the drug discovery process between kinases and GTPases.
Kinase GTPase
Nucleotide binding domain structure Potential binding pockets Smooth and globular
Nucleotide dissociation constant Nanomolar to micromolar Picomolar to nanomolar
Biochemical and cellular assay availability Ample In development
Protein concentration in biochemical assays Low nanomolar High nanomolar to low micromolar
Nucleotide binding and hydrolysis regulation Different domains on the same protein Separate GEF and GAPs
Function range Mostly signal transduction Including signal transduction, cytoskeleton organization,
macromolecule transport
Misregulation Hyperactive Hyperactive and hypoactive
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has been made in the GTPase ﬁeld in recent years. This has
been demonstrated in several ways. First, structure-based rational
design and in silico screening have provided signiﬁcant momen-
tum in small molecule discovery and development (Gao et al.,
2004; Shima et al., 2013). Second, in analogy to the search
for the type II and type III inhibitors for the kinases, efforts
have been directed to search for molecules that can either mod-
ulate the interactions between a GTPase and its effectors or
that can directly inhibit the effector proteins. For example, vir-
tual screening has identiﬁed Rho and Rac inhibitors that block
the interactions between the GTPase and its GEF (Gao et al.,
2004; Shang et al., 2012). From an in silico docking study, a
Ras inhibitor was developed to inhibit the interactions between
Ras and its downstream effector proteins (Shima et al., 2013).
Compounds that directly inhibit the catalytic activities of the
GEFs of Rho and Rac have also been developed (Nishikimi et al.,
2012; Shang et al., 2013). Third, screening methods have evolved
which are automated and cost efﬁcient. A small molecule that
inhibits the interactions between the farnesylated K-Ras and the
prenyl-binding protein PDEδ was discovered from screening and
shown to inhibit oncogenic Ras signaling (Zimmermann et al.,
2013).
In our laboratory, we have developed a ﬂow cytometry based
multiplex screening and assay format (Surviladze et al., 2012)
where different GTPases were linked to microsphere bead sets
which had distinct ﬂuorescence intensities and could be separated
in the red ﬂuorescence channel with excitation/emission of
635/750LP nm on a ﬂow cytometer. The extent of ﬂuorescent
GTPbinding to the individualGTPases in the presence of test com-
pounds was analyzed by another channel with excitation/emission
of 480/530 nm. This method allowed the potency and selectivity
of a compound toward several GTPases to be revealed simultane-
ously. Also smaller quantities of GTPases were used compared to
plate based homogeneous assays. Through screening the molecu-
lar library smallmolecule repository (MLSMR),we have identiﬁed
a pan-GTPases inhibitor (Hong et al., 2010), Rho family GTPases
inhibitors (Surviladze et al., 2010c, 2012), as well as a selective
inhibitor for individual GTPase Cdc42 (Surviladze et al., 2010b;
Hong et al., 2013). In addition, activators of GTP binding were
also pursued along with the inhibitor search. Three molecules
CID888706, CID7345532, and CID2160985 have been found to
increase ﬂuorescent GTP binding to multiple GTPases (Survi-
ladze et al., 2010a). Using CID888706 as an example, biochemical
studies conﬁrmed that the compound had an EC50 in the low
micromolar range and suggested an allosteric binding mecha-
nism. Cellular assays also demonstrated that the compound could
enhance the activity of Rho GTPases in regulating cytoskeleton
reorganization.
FIGURE 3 | A flow chart showing the progress in the development
of GTPase activity modulators. The initial GTPase inhibitors were
natural products that inhibit GTPase prenylation and signal
transduction. In the last several years, through in silico screening
and rational design, inhibitors that blocked protein interactions and
GEF enzymatic activities were identiﬁed. On the other hand, single
compound library screening revealed molecules that interfere with
either protein interactions or nucleotide binding. The most recent
progress lies in the combinatorial library screening in a multiplex
format.
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We have previously reported the results of a collaborative
screening effort with Torrey Pines Institute for Molecular Studies
(TPIMS) involving libraries generated by combinatorial synthe-
sis and a duplex of G protein coupled receptors (GPCRs) which
resulted in a large number of the most active small molecules
for the formyl peptide receptors (FPRs) ever reported (Medina-
Franco et al., 2013; Pinilla et al., 2013; Santos et al., 2013).
The combinatorial library contains more than 5 million small
molecules and 26 million peptides. These are grouped into 37
scaffolds each of which has combinatorial derivatives of multi-
ple functional groups (Pinilla et al., 2013). Recently, we probed
this chemical library for activity modulators for GTPases in a
multiplex of Rab5, Rab7, Cdc42, Ras wild type and Ras mutant
Q61L with Rho and Rac screened as individual targets1. The
GTPases used either have been associated with Parkinson’s disease
or have signiﬁcant roles in other illnesses. Interestingly, activa-
tors selective toward subfamilies of GTPases, including Ras and its
mutant, were identiﬁed. Although the Ras inhibitors would usu-
ally be pursued, the activators of Ras can have their own uses,
such as to generate cellular and animal models with aberrant
Ras signaling which could be more convenient than the genetic
approach. Moreover, if structures of the activator bound GTPases
could be obtained, they would provide instructive information on
designing GTPase activity regulators. Future collaborative stud-
ies will focus on the deconvolution of the combinatorial mixtures
and the characterization of the individual or subgroups of com-
pounds. The progress in the development of GTPase activity
modulators has been recapitulated in a ﬂow chart, as shown in
Figure 3.
In summary, although the causes of the Parkinson’s disease
have not been elucidated, the accumulating studies have shown
that several cellular physiological processes are likely to be impli-
cated in the initiation and progression of the disease, such as
organelle homeostasis, axon growth and maintenance, mitochon-
dria dynamic changes, organelle trafﬁc, oxidative homeostasis,
and neuronal cell differentiation. Enhanced by GWAS, genes
implicated in the familial forms of Parkinson’s disease have been
increasingly identiﬁed and their links to the disease have been
studied. Multiple GTPases are involved in the disease related pro-
cesses and some genes identiﬁed from GWAS encode GTPases.
GTPases are therefore rational therapeutic targets for Parkinson’s
disease. However, GTPase drug discovery has been progressing
more slowly and only more recently when compared to its kinase
counterpart. This is likely due to the fundamentally different
nature of the two classes of proteins, and the different roles they
have in cell physiology. Yet, lessons learned from the kinase ﬁeld,
such as rational design and combinatorial approaches, joined by
the rapid growth of structural information, promise a leap for-
ward in GTPase drug discovery and development in the near
future.
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